Q-omics provides the consensus-scored PTS profile across patient tissues and cancer cell-line models. PTS expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PTS is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, PTS RNA expression shows 18,646 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, and UVM as cancer lineages where PTS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTS survival associations across molecular data types. PTS RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTS RNA expression–survival associations across cancer types. High PTS expression shows unfavorable associations in HNSC, ACC, UVM, BRCA and LGG, but favorable associations in THCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PTS RNA expression.
This table summarizes PTS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTS shows lower tumor expression in KIRC and higher tumor expression in HNSC, LUAD, COAD, LUSC and BRCA. The HNSC box plot shows higher PTS RNA expression in tumor versus normal tissue (log2 FC = +0.891, t-test p < 0.001).
This table shows molecular features associated with PTS in patient tissues and cancer cell lines. In patient samples, PTS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
